Chronic Trace, Inc.
Chronic Trace develops a research-stage Software-as-a-Medical-Device (SaMD) platform that transforms video captured on commodity devices into objective, manipulation-resistant indices of brain health. The technology fuses involuntary physiological signals and task-based performance measures into a single calibrated index for decision support in areas such as concussion management, stroke triage, psychiatric assessment, and neurodegenerative risk monitoring. The platform is undergoing pivotal validation, with multiple patents pending, and operates under HIPAA-aligned data handling protocols. Clinical decisions based on its outputs require interpretation by licensed health professionals.
Industries
N/A
Products
Research-stage Software-as-a-Medical-Device that captures physiological and cognitive signals using short video from commodity devices, outputting multiple calibrated indices for clinical decision support.
Research-stage Software-as-a-Medical-Device that captures physiological and cognitive signals using short video from commodity devices, outputting multiple calibrated indices for clinical decision support.
Expertise Areas
- Neuro-assessment
- Digital health decision support
- Traumatic brain injury monitoring
- Manipulation-resistant digital biomarkers
Key Technologies
- Computer vision-based video assessment
- Oculomotor signal analysis
- Postural sway quantification
- Remote photoplethysmography (rPPG)
Key People
News & Updates
Discussion of recovery monitoring and the core importance of tracking return-to-baseline in brain injury assessment, describing the motivation behind Chronic Trace's methodology.
Field comparison of conventional concussion tests regarding their resistance to manipulation, contextualizing the need for involuntary biomarker-based assessment.
Explains baseline assessment limitations, issues of intentional manipulation, and the potential for objective digital biomarker approaches.
Plain account of the company's current regulatory posture, including FDA pathway, and the facts/limitations of marketing clinical claims before validation.
Monthly company updates (patents, field cohort progress, regulatory milestones, engineering, and team) for transparency and validation progress reporting.
Dispersion-based method for integrating involuntary signals into a calibrated brain health index.
Discussion of recovery monitoring and the core importance of tracking return-to-baseline in brain injury assessment, describing the motivation behind Chronic Trace's methodology.
Field comparison of conventional concussion tests regarding their resistance to manipulation, contextualizing the need for involuntary biomarker-based assessment.
Explains baseline assessment limitations, issues of intentional manipulation, and the potential for objective digital biomarker approaches.
Plain account of the company's current regulatory posture, including FDA pathway, and the facts/limitations of marketing clinical claims before validation.
Monthly company updates (patents, field cohort progress, regulatory milestones, engineering, and team) for transparency and validation progress reporting.
Dispersion-based method for integrating involuntary signals into a calibrated brain health index.